Status:
RECRUITING
Hepatic Safety of Statin Use in Neurology Inpatients
Lead Sponsor:
Shanghai Yueyang Integrated Medicine Hospital
Conditions:
Statin Adverse Reaction
Eligibility:
All Genders
18-85 years
Brief Summary
This research employs a cross-sectional study and a retrospective cohort study to analyze the liver safety of statin use among inpatients in the neurology department in China from different perspectiv...
Eligibility Criteria
Inclusion
- Patients hospitalized in the Department of Neurology of Yueyang Hospital from June 2020 to February 2023.
- Age ≥18 and ≤85 years old, both sexes.
- Meet the diagnostic criteria of cerebrovascular disease (L1-8B0), headache disease (L1-8A8) and dizziness and vertigo (MB48) in ICD-11.
Exclusion
- Incomplete medical history.
- 1 days ≤ patients with \< 7 days of prior statin use.
- Patients with malignant tumors (ICD-11 code L1-2A0, L1-2A2, L1-2B5, L1-2E6 diseases) and hematological diseases (ICD-11 code L1-3A0, L1-3B1, L1-3B8 diseases).
Key Trial Info
Start Date :
August 10 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 10 2024
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT06592196
Start Date
August 10 2024
End Date
December 10 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Yueyang Integrated Medicine Hospital
Shanghai, Shanghai Municipality, China